77 related articles for article (PubMed ID: 21396849)
1. Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR).
Sciarra A; Panebianco V; Salciccia S; Lisi D; Alfarone A; Gentilucci A; Parente U; Cattarino S; Passariello R; Gentile V
Urol Oncol; 2012 Sep; 30(5):614-9. PubMed ID: 21396849
[TBL] [Abstract][Full Text] [Related]
2. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy.
Sciarra A; Panebianco V; Ciccariello M; Salciccia S; Cattarino S; Lisi D; Gentilucci A; Alfarone A; Bernardo S; Passariello R; Gentile V
Clin Cancer Res; 2010 Mar; 16(6):1875-83. PubMed ID: 20197480
[TBL] [Abstract][Full Text] [Related]
3. Locally advanced prostate cancer: three-dimensional magnetic resonance spectroscopy to monitor prostate response to therapy.
Valentini AL; Gui B; D'Agostino GR; Mattiucci G; Clementi V; Di Molfetta IV; Bonomo P; Mantini G
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):719-24. PubMed ID: 22436789
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
[TBL] [Abstract][Full Text] [Related]
5. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer.
Sciarra A; Panebianco V; Salciccia S; Osimani M; Lisi D; Ciccariello M; Passariello R; Di Silverio F; Gentile V
Eur Urol; 2008 Sep; 54(3):589-600. PubMed ID: 18226441
[TBL] [Abstract][Full Text] [Related]
6. Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy--a secondary analysis of irish clinical oncology research group 97-01.
Mydin AR; Dunne MT; Finn MA; Armstrong JG
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):101-8. PubMed ID: 22658512
[TBL] [Abstract][Full Text] [Related]
7. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
9. Value of magnetic resonance spectroscopy (MSR) and dynamic contrast-enhanced magnetic resonance (DCEMR) imaging for the characterization of high-grade prostatic intraepithelial neoplasia (HGPIN) foci.
Sciarra A; Panebianco V; Salciccia S; Gentilucci A; Alfarone A; Dimare L; Lisi D; Catturino S; Di Pierro G; Von Heland M; Ciccariello M; Passariello R; Gentile V
Urol Oncol; 2011; 29(6):634-40. PubMed ID: 19914107
[TBL] [Abstract][Full Text] [Related]
10. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer.
Pickett B; Kurhanewicz J; Coakley F; Shinohara K; Fein B; Roach M
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1047-55. PubMed ID: 15519774
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
12. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
D'Amico AV; Saegaert T; Chen MH; Renshaw AA; George D; Oh W; Kantoff PW
Cancer; 2002 Jul; 95(2):275-80. PubMed ID: 12124826
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging.
Costouros NG; Coakley FV; Westphalen AC; Qayyum A; Yeh BM; Joe BN; Kurhanewicz J
AJR Am J Roentgenol; 2007 Mar; 188(3):812-6. PubMed ID: 17312072
[TBL] [Abstract][Full Text] [Related]
15. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.
Oh WK; Kaplan ID; Febbo P; Prisby J; Manola J; Kaufman DS; Kantoff PW
Am J Clin Oncol; 2003 Jun; 26(3):312-6. PubMed ID: 12796607
[TBL] [Abstract][Full Text] [Related]
17. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
18. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.
Kumar R; Nayyar R; Kumar V; Gupta NP; Hemal AK; Jagannathan NR; Dattagupta S; Thulkar S
Urology; 2008 Oct; 72(4):859-63. PubMed ID: 18329078
[TBL] [Abstract][Full Text] [Related]
19. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
20. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
